Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China
Date of Publication:2023-05-04 Hits:
Affiliation of Author(s):公共卫生学院
Journal:Frontiers in Immunology
Document Code:AACF629AB0EF4A22870C33F9DE38ECDF
Volume:14
Number of Words:7
Translation or Not:no
Date of Publication:2023-05-04
